Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 3
2012 5
2013 4
2014 6
2015 1
2016 2
2017 3
2018 1
2019 4
2020 2
2021 3
2022 7
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.
Muik A, Garralda E, Altintas I, Gieseke F, Geva R, Ben-Ami E, Maurice-Dror C, Calvo E, LoRusso PM, Alonso G, Rodriguez-Ruiz ME, Schoedel KB, Blum JM, Sänger B, Salcedo TW, Burm SM, Stanganello E, Verzijl D, Vascotto F, Sette A, Quinkhardt J, Plantinga TS, Toker A, van den Brink EN, Fereshteh M, Diken M, Satijn D, Kreiter S, Breij ECW, Bajaj G, Lagkadinou E, Sasser K, Türeci Ö, Forssmann U, Ahmadi T, Şahin U, Jure-Kunkel M, Melero I. Muik A, et al. Among authors: altintas i. Cancer Discov. 2022 May 2;12(5):1248-1265. doi: 10.1158/2159-8290.CD-21-1345. Cancer Discov. 2022. PMID: 35176764 Free PMC article. Clinical Trial.
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.
Muik A, Adams 3rd HC, Gieseke F, Altintas I, Schoedel KB, Blum JM, Sänger B, Burm SM, Stanganello E, Verzijl D, Spires VM, Vascotto F, Toker A, Quinkhardt J, Fereshteh M, Diken M, Satijn DPE, Kreiter S, Ahmadi T, Breij ECW, Türeci Ö, Sasser K, Sahin U, Jure-Kunkel M. Muik A, et al. Among authors: altintas i. J Immunother Cancer. 2022 Jun;10(6):e004322. doi: 10.1136/jitc-2021-004322. J Immunother Cancer. 2022. PMID: 35688554 Free PMC article.
Ten simple rules for writing and sharing computational analyses in Jupyter Notebooks.
Rule A, Birmingham A, Zuniga C, Altintas I, Huang SC, Knight R, Moshiri N, Nguyen MH, Rosenthal SB, Pérez F, Rose PW. Rule A, et al. Among authors: altintas i. PLoS Comput Biol. 2019 Jul 25;15(7):e1007007. doi: 10.1371/journal.pcbi.1007007. eCollection 2019 Jul. PLoS Comput Biol. 2019. PMID: 31344036 Free PMC article. No abstract available.
Integrating plant physiology into simulation of fire behavior and effects.
Dickman LT, Jonko AK, Linn RR, Altintas I, Atchley AL, Bär A, Collins AD, Dupuy JL, Gallagher MR, Hiers JK, Hoffman CM, Hood SM, Hurteau MD, Jolly WM, Josephson A, Loudermilk EL, Ma W, Michaletz ST, Nolan RH, O'Brien JJ, Parsons RA, Partelli-Feltrin R, Pimont F, Resco de Dios V, Restaino J, Robbins ZJ, Sartor KA, Schultz-Fellenz E, Serbin SP, Sevanto S, Shuman JK, Sieg CH, Skowronski NS, Weise DR, Wright M, Xu C, Yebra M, Younes N. Dickman LT, et al. Among authors: altintas i. New Phytol. 2023 May;238(3):952-970. doi: 10.1111/nph.18770. Epub 2023 Feb 14. New Phytol. 2023. PMID: 36694296 Review.
Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI.
Azam TU, Shadid HR, Blakely P, O'Hayer P, Berlin H, Pan M, Zhao P, Zhao L, Pennathur S, Pop-Busui R, Altintas I, Tingleff J, Stauning MA, Andersen O, Adami ME, Solomonidi N, Tsilika M, Tober-Lau P, Arnaoutoglou E, Keitel V, Tacke F, Chalkias A, Loosen SH, Giamarellos-Bourboulis EJ, Eugen-Olsen J, Reiser J, Hayek SS; International Study of Inflammation in COVID-19. Azam TU, et al. Among authors: altintas i. J Am Soc Nephrol. 2020 Nov;31(11):2725-2735. doi: 10.1681/ASN.2020060829. Epub 2020 Sep 22. J Am Soc Nephrol. 2020. PMID: 32963090 Free PMC article.
An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
Muik A, Altintas I, Gieseke F, Schoedel KB, Burm SM, Toker A, Salcedo TW, Verzijl D, Eisel D, Grunwitz C, Kranz LM, Vormehr M, Satijn DPE, Diken M, Kreiter S, Sasser K, Ahmadi T, Türeci Ö, Breij ECW, Jure-Kunkel M, Sahin U. Muik A, et al. Among authors: altintas i. Oncoimmunology. 2022 Feb 16;11(1):2030135. doi: 10.1080/2162402X.2022.2030135. eCollection 2022. Oncoimmunology. 2022. PMID: 35186440 Free PMC article.
Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID-19.
Luo S, Vasbinder A, Du-Fay-de-Lavallaz JM, Gomez JMD, Suboc T, Anderson E, Tekumulla A, Shadid H, Berlin H, Pan M, Azam TU, Khaleel I, Padalia K, Meloche C, O'Hayer P, Catalan T, Blakely P, Launius C, Amadi KM, Pop-Busui R, Loosen SH, Chalkias A, Tacke F, Giamarellos-Bourboulis EJ, Altintas I, Eugen-Olsen J, Williams KA, Volgman AS, Reiser J, Hayek SS; ISIC (International Study of Inflammation in COVID‐19) Group. Luo S, et al. Among authors: altintas i. J Am Heart Assoc. 2022 Sep 20;11(18):e025198. doi: 10.1161/JAHA.122.025198. Epub 2022 Aug 4. J Am Heart Assoc. 2022. PMID: 35924778 Free PMC article.
Perspectives on automated composition of workflows in the life sciences.
Lamprecht AL, Palmblad M, Ison J, Schwämmle V, Al Manir MS, Altintas I, Baker CJO, Ben Hadj Amor A, Capella-Gutierrez S, Charonyktakis P, Crusoe MR, Gil Y, Goble C, Griffin TJ, Groth P, Ienasescu H, Jagtap P, Kalaš M, Kasalica V, Khanteymoori A, Kuhn T, Mei H, Ménager H, Möller S, Richardson RA, Robert V, Soiland-Reyes S, Stevens R, Szaniszlo S, Verberne S, Verhoeven A, Wolstencroft K. Lamprecht AL, et al. Among authors: altintas i. F1000Res. 2021 Sep 7;10:897. doi: 10.12688/f1000research.54159.1. eCollection 2021. F1000Res. 2021. PMID: 34804501 Free PMC article.
41 results